Home › Crohn's Disease › Illinois
Crohn's Disease clinical trials in Illinois
18 studies for Crohn's Disease are looking for participants at sites in Illinois.
Cities in Illinois
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gi Alliance - Glenview /ID# 283932, Glenview
- Illinois Gastroenterology Group /ID# 283933, Gurnee
- Southwest Gastroenterology - Oak Lawn /ID# 280841, Oak Lawn
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 29, 2026 · NCT07697456A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- University of Chicago Medical Center ( Site 5066), Chicago
- Endeavor Health ( Site 5018), Evanston
- GI ALLIANCE - GURNEE ( Site 5003), Gurnee
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 29, 2026 · NCT06430801Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- University of Chicago Medical Center /ID# 267400, Chicago
- OSF St. Francis Medical Center /ID# 266973, Peoria
- Springfield Clinic Main Campus /ID# 267434, Springfield
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT06548542Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Rush University Medical Center, Chicago
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT06937099A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Illinois Gastroenterology Group d/b/a GI Alliance - Gurnee-Site Number: 8400049, Gurnee
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184944An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Rush University Medical Center-Site Number: 8400015, Chicago
- Midwest Digestive Health and Nutrition-Site Number: 8400136, Des Plaines
- GI Alliance - Glenview-Site Number: 8400068, Glenview
- and 1 more
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184931A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
- Rush University Medical Center, Chicago
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07483099A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- Rush University Medical Center, Chicago
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07483073A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Yapp, Rockford M.D. (Private Practice), Downers Grove
- GI Alliance - Glenview, Glenview
- Gastroenterology and Internal Medicine Specialists, SC, Lake Barrington
- and 3 more
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Sep 15, 2026 · NCT06581328A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- University of Chicago Medicine, Chicago
RecruitingPhase 4
Ages 18 to 70 · All sexes · Updated Sep 9, 2026 · NCT06045754Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- University of Chicago Medicine, Chicago
Recruiting
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT05230173Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- OSF St. Francis Medical Center /ID# 262192, Peoria
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Jun 24, 2026 · NCT06332534A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Advocate Children's Hospital Park Ridge, Park Ridge
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Jun 22, 2026 · NCT06405087A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Advocate Children's Hospital - Park Ridge - PIN, Park Ridge
RecruitingPhase 3
Ages 2 and older · All sexes · Updated May 7, 2026 · NCT05442567A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Advocate Children's Hospital Park Ridge, Park Ridge
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated May 5, 2026 · NCT04779320Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Northwestern University, Evanston
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Apr 27, 2026 · NCT06456593A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Glenview
- Mirador Therapeutics Selected Site, Gurnee
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Mar 12, 2026 · NCT07113522Treatment of Moderate to Severe Refractory Crohn's Disease
- Northwestern, Chicago
- University of Chicago, Chicago
RecruitingPhase 1/2
Ages 18 to 65 · All sexes · Updated Dec 10, 2025 · NCT06721962From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.